Ultomiris Европейски съюз - български - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - Хемоглобинурия, пароксизма - Селективни имуносупресори - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Vyvgart Европейски съюз - български - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - Имуносупресори - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Acetylcysteine Rompharm 600 mg effervescent tablets България - български - Изпълнителна агенция по лекарствата

acetylcysteine rompharm 600 mg effervescent tablets

600 mg effervescent tablets

STROMEASE 25 mg/ml капки за очи, разтвор за кучета и котки 25 mg/ml България - български - БАБХ (Българска агенция по безопасност на храните)

stromease 25 mg/ml капки за очи, разтвор за кучета и котки 25 mg/ml

domes pharma - Ацетилцистеин - разтвор, капки за очи - 25 mg/ml - котки, кучета

Mucosoft 600 mg powder for oral solution България - български - Изпълнителна агенция по лекарствата

mucosoft 600 mg powder for oral solution

Адифарм ЕАД - Ацетилцистеин - 600 mg powder for oral solution

Acc 100 mg powder for oral solution България - български - Изпълнителна агенция по лекарствата

acc 100 mg powder for oral solution

hexal ag - Ацетилцистеин - 100 mg powder for oral solution

Acc Kid 20 mg/ml powder for oral solution България - български - Изпълнителна агенция по лекарствата

acc kid 20 mg/ml powder for oral solution

hexal ag - Ацетилцистеин - 20 mg/ml powder for oral solution

Acc Acute 200 mg powder for oral solution България - български - Изпълнителна агенция по лекарствата

acc acute 200 mg powder for oral solution

hexal ag - Ацетилцистеин - 200 mg powder for oral solution

Fluimucil 100 mg granules for oral solution България - български - Изпълнителна агенция по лекарствата

fluimucil 100 mg granules for oral solution

Анджелини Фарма България ЕООД - Ацетилцистеин - 100 mg granules for oral solution

Fluimucil 200 mg granules for oral solution България - български - Изпълнителна агенция по лекарствата

fluimucil 200 mg granules for oral solution

Анджелини Фарма България ЕООД - Ацетилцистеин - 200 mg granules for oral solution